Kolon Life Science Inc.

KOSDAQ:A102940 Stock Report

Market Cap: ₩227.1b

Kolon Life Science Valuation

Is A102940 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A102940 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A102940's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A102940's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A102940?

Key metric: As A102940 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A102940. This is calculated by dividing A102940's market cap by their current revenue.
What is A102940's PS Ratio?
PS Ratio1.6x
Sales₩140.27b
Market Cap₩227.10b

Price to Sales Ratio vs Peers

How does A102940's PS Ratio compare to its peers?

The above table shows the PS ratio for A102940 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1x
A001630 Chong Kun Dang Holdings
0.3x5.0%₩250.9b
A007570 Ilyang PharmaceuticalLtd
0.6xn/a₩203.6b
A271980 Jeil PharmaceuticalLtd
0.3xn/a₩183.5b
A058820 CMG Pharmaceutical
2.9xn/a₩273.8b
A102940 Kolon Life Science
1.6xn/a₩227.1b

Price-To-Sales vs Peers: A102940 is expensive based on its Price-To-Sales Ratio (1.6x) compared to the peer average (1x).

Price to Sales Ratio vs Industry

How does A102940's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
A009290 Kwang Dong Pharmaceutical
0.1xn/aUS$163.00m
A002620 Jeil Pharma Holdings
0.2xn/aUS$95.63m
A000230 Ildong Holdings
0.1xn/aUS$56.11m
No more companies available in this PS range
A102940 1.6xIndustry Avg. 0.8xNo. of Companies15PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A102940 is expensive based on its Price-To-Sales Ratio (1.6x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A102940's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A102940 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A102940's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

J2KBIO

₩56.2b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,830.00

7D

6.0%

1Y

n/a

Hugel

₩2.9t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,000.00

7D

-3.4%

1Y

75.9%

Dong-A ST

₩560.3b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩62,400.00

7D

-1.9%

1Y

8.8%